News

As the official COVID-19 emergency is declared over, our Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, reflects on the public health response, the scientific successes, and the shortcomings that were experienced.

Recognizing high-risk patients is crucial for effective management of UTIs, explains Kim Leuthner, PharmD, FIDSA.

The federal lawsuit filed in court looks to stop the government’s plan to negotiate therapy prices.

COVID-19 and CMV coinfection caused the premature aging of immune systems, leading to a greater risk of cardiovascular disease at an earlier age, the study authors said.

With the CDC’s recent warning about it, this fungal infection is becoming more prevalent and is often multidrug resistant. Here are some infection prevention strategies to protect against its spread in health care facilities, where it is most common.

The federal agency gave Merck the nod to use the company's antiviral as prophylaxis for Cytomegalovirus Disease (CMV), postoperatively.

Following household COVID-19 transmissions for over 3 years, investigators found that 70.4% had a pediatric index case.

By repopulating the gut with healthy and diverse microbiota, Vowst aims to prevent further C diff recurrences and restore patients' quality of life.

A new study looked at the risk of hepatitis B and C as a result of exposure from such procedures.

Findings indicate that while the severity of health impairment decreases over time, 18% of unvaccinated participants still experience symptoms up to 2 years after infection.

From outbreaks to breakthroughs, these are the biggest infectious disease headlines from the past week.

The area under the concentration-time curve (AUC) for vancomycin at discharge was the only modifiable factor found that was independently associated with patient safety outcomes.

How does the diagnosis rate of mental health disorders after COVID-19 compare to that of other respiratory infections?

A new documentary looks at dealing with the condition long-term, and serves as a microcosm for how people suffer through chronic conditions and diseases, and may not get the help they need.

Atea Pharmaceutical’s investigational therapy, bemnifosbuvir, is in a phase 3 trial for the former and phase 2 for the latter.

The FDA's decision to approve Abrysvo was based on data from a Phase 3 clinical trial, which demonstrated the RSV vaccine's efficacy, immunogenicity, and safety in adults aged 60 and older.

Neutralizing antibodies were initially lowest among Janssen vaccine recipients, but this all changed 6 months after vaccination.

European medical committee offers favorable opinion for people with all forms of renal impairment including those on dialysis.

Sleep as a shield: A new study reveals that sleeping well before COVID-19 infection reduces the risk of post–COVID-19 condition (long COVID).

Analysis of symptoms present six months or more after SARS-CoV-2 infection was used to develop a composite scoring framework for identifying postacute sequelae of SARS-CoV-2 infection (PASC) as a new condition.

The Omicron variant caused the most symptoms in pediatric patients. However, there were no differences in adverse outcomes by COVID-19 variant.

A clinician talks about reducing antibiotic treatment duration for urinary tract infections (UTI).

Investigators revisit an 80-year-old antimicrobial to reduce its toxicity while preserving its activity against drug resistant gram-negative bacteria.

A large study of patients treated in the intensive care unit (ICU) demonstrates common genetic links that point to a potential reason for people progressing to life-threatening forms of the respiratory virus.

The Mexican Ministry of Health sent the CDC a list of over 200 US patients who may have been exposed to the fungal infection.

There has been a low uptake of bivalent mRNA booster vaccines in older adults, despite a high efficacy of preventing severe and fatal COVID-19.

The innovative antibiotic Xacduro has received FDA approval for its efficacy against ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus. The intravenous therapy combines sulbactam and durlobactamto target multidrug-resistant and carbapenem-resistant strains.

This is the first oral antiviral to get through the regulatory process and is indicated for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.